278 related articles for article (PubMed ID: 31637237)
1. Targeted Approaches to Inhibit Sialylation of Multiple Myeloma in the Bone Marrow Microenvironment.
Natoni A; Bohara R; Pandit A; O'Dwyer M
Front Bioeng Biotechnol; 2019; 7():252. PubMed ID: 31637237
[TBL] [Abstract][Full Text] [Related]
2. Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse model.
Natoni A; Farrell ML; Harris S; Falank C; Kirkham-McCarthy L; Macauley MS; Reagan MR; O'Dwyer M
Haematologica; 2020; 105(2):457-467. PubMed ID: 31101754
[TBL] [Abstract][Full Text] [Related]
3. Aberrant Sialylation in Cancer: Therapeutic Opportunities.
Munkley J
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077781
[TBL] [Abstract][Full Text] [Related]
4. Targeting Selectins and Their Ligands in Cancer.
Natoni A; Macauley MS; O'Dwyer ME
Front Oncol; 2016; 6():93. PubMed ID: 27148485
[TBL] [Abstract][Full Text] [Related]
5. The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma.
Glavey SV; Manier S; Natoni A; Sacco A; Moschetta M; Reagan MR; Murillo LS; Sahin I; Wu P; Mishima Y; Zhang Y; Zhang W; Zhang Y; Morgan G; Joshi L; Roccaro AM; Ghobrial IM; O'Dwyer ME
Blood; 2014 Sep; 124(11):1765-76. PubMed ID: 25061176
[TBL] [Abstract][Full Text] [Related]
6. Serum protein N-glycosylation changes in multiple myeloma.
Zhang Z; Westhrin M; Bondt A; Wuhrer M; Standal T; Holst S
Biochim Biophys Acta Gen Subj; 2019 May; 1863(5):960-970. PubMed ID: 30844485
[TBL] [Abstract][Full Text] [Related]
7. DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment.
Hewett DR; Vandyke K; Lawrence DM; Friend N; Noll JE; Geoghegan JM; Croucher PI; Zannettino ACW
Neoplasia; 2017 Dec; 19(12):972-981. PubMed ID: 29091798
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
9. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment.
Shay G; Tauro M; Loiodice F; Tortorella P; Sullivan DM; Hazlehurst LA; Lynch CC
Oncotarget; 2017 Jun; 8(26):41827-41840. PubMed ID: 28611279
[TBL] [Abstract][Full Text] [Related]
11. MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment.
Raimondi L; De Luca A; Morelli E; Giavaresi G; Tagliaferri P; Tassone P; Amodio N
Biomed Res Int; 2016; 2016():6504593. PubMed ID: 26881223
[TBL] [Abstract][Full Text] [Related]
12. Adhesive interactions of human multiple myeloma cell lines with different extracellular matrix molecules.
Kibler C; Schermutzki F; Waller HD; Timpl R; Müller CA; Klein G
Cell Adhes Commun; 1998 Jun; 5(4):307-23. PubMed ID: 9762471
[TBL] [Abstract][Full Text] [Related]
13. Adhesion molecules in multiple myeloma oncogenesis and targeted therapy.
Bou Zerdan M; Nasr L; Kassab J; Saba L; Ghossein M; Yaghi M; Dominguez B; Chaulagain CP
Int J Hematol Oncol; 2022 Apr; 11(2):IJH39. PubMed ID: 35663420
[TBL] [Abstract][Full Text] [Related]
14. Multiple myeloma: the bone marrow microenvironment and its relation to treatment.
Andrews SW; Kabrah S; May JE; Donaldson C; Morse HR
Br J Biomed Sci; 2013; 70(3):110-20. PubMed ID: 24273897
[TBL] [Abstract][Full Text] [Related]
15. Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing.
Moschetta M; Kawano Y; Sacco A; Belotti A; Ribolla R; Chiarini M; Giustini V; Bertoli D; Sottini A; Valotti M; Ghidini C; Serana F; Malagola M; Imberti L; Russo D; Montanelli A; Rossi G; Reagan MR; Maiso P; Paiva B; Ghobrial IM; Roccaro AM
Curr Osteoporos Rep; 2017 Oct; 15(5):499-506. PubMed ID: 28889371
[TBL] [Abstract][Full Text] [Related]
16. The hemopoietic stem cell niche versus the microenvironment of the multiple myeloma-tumor initiating cell.
Zipori D
Cancer Microenviron; 2010 Feb; 3(1):15-28. PubMed ID: 21209772
[TBL] [Abstract][Full Text] [Related]
17. Adipose, Bone, and Myeloma: Contributions from the Microenvironment.
McDonald MM; Fairfield H; Falank C; Reagan MR
Calcif Tissue Int; 2017 May; 100(5):433-448. PubMed ID: 27343063
[TBL] [Abstract][Full Text] [Related]
18. Lectin staining and Western blot data showing differential sialylation of nutrient-deprived cancer cells to sialic acid supplementation.
Badr HA; AlSadek DM; Mathew MP; Li CZ; Djansugurova LB; Yarema KJ; Ahmed H
Data Brief; 2015 Dec; 5():481-8. PubMed ID: 26629491
[TBL] [Abstract][Full Text] [Related]
19. Anticancer approach by targeted activation of a global inhibitor of sialyltransferases with acrolein.
Kasahara T; Chang TC; Yoshioka H; Urano S; Egawa Y; Inoue M; Tahara T; Morimoto K; Pradipta AR; Tanaka K
Chem Sci; 2024 Jun; 15(25):9566-9573. PubMed ID: 38939146
[TBL] [Abstract][Full Text] [Related]
20. Multiple myeloma cells promote migration of bone marrow mesenchymal stem cells by altering their translation initiation.
Dabbah M; Attar-Schneider O; Zismanov V; Tartakover Matalon S; Lishner M; Drucker L
J Leukoc Biol; 2016 Oct; 100(4):761-770. PubMed ID: 27272311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
